newsfilter
← Latest News
ACCESS Newswire·

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

- Dermata announced positive topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research clinical trial, achieving all co-primary endpoints -- Dermata entered into a Clinical Trial